<DOC>
	<DOCNO>NCT00891748</DOCNO>
	<brief_summary>The study objective evaluate feasibility three instillation immunostimulating gene therapy ( AdCD40L ) patient urinary bladder cancer . Tolerance , toxicity immunological parameter evaluate post treatment .</brief_summary>
	<brief_title>Safety Study AdCD40L Gene Therapy Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>Histologically proven diagnosis transitional cell carcinoma bladder ECOG 02 18 year age older sign informed consent Phase I part : patient schedule cystectomy Woman childbearing potential ( fertile woman ) Other malignancy within 5 year study , except nonmelanoma skin cancer Metastatic disease Previous exposure intravesical therapy bladder cancer : within 3 month chemotherapy within 6 month BCG therapy . Previous pelvic radiation treatment cytotoxic , immunologic chemotherapeutic agent nonmalignant condition within 5 year study . Clinically abnormal hepatic , renal bone marrow function , coagulation disorder opinion investigator . Chronic urinary tract infection . Serous infection G.U . surgery , except bladder cancer , within 1 month study require 3 day hospital care . Vesical capacity &lt; 150mL and/or vesical obstruction residual &gt; 150 mL spontaneous voiding . Previous exposure experimental drug within 3 month enrolment . Any significant medical psychiatric illness would prevent patient give informed consent follow study procedure . Patients presently urothelial cell carcinoma upper G.U . tract Patients systemic autoimmune disease Patients consent tissue blood sample store biobank Treatment systemically administer corticosteroid NSAID within 4 week prior first study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>